CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies
Caribou Biosciences’ 2025 outlook aimed for key trial readouts for 2 most cancers cell therapies within the first half of ...
Caribou Biosciences’ 2025 outlook aimed for key trial readouts for 2 most cancers cell therapies within the first half of ...
Most cancers is effectively represented within the Astellas Pharma portfolio and pipeline, however the drugmaker has made diversification a key ...
Neuroscience drug developer Lundbeck is increasing its scope to epilepsy through the $2.6 billion acquisition of Longboard Prescribed drugs, an ...
For the primary time, researchers have created genetically modified fruit flies that may turn into hooked on cocaine. The flies...
Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.
Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.